Read this manager's filing book
Disclosed positions
Exome Asset Management LLC: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- GUARDANT HEALTH INC
- Ticker
- GH
- Class
- COM
- Reported value
- $10,127,025
- Reported amount
- 67,500
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001420506-26-001714Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| GUARDANT HEALTH INC | GH | COM | $10,127,025 | 67,500 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $9,107,962 | 27,205 | SH | None |
| TG THERAPEUTICS INC | TGTX | COM | $9,060,430 | 164,915 | SH | None |
| COGENT BIOSCIENCES INC | COGT | COM | $8,147,240 | 210,523 | SH | None |
| IONIS PHARMACEUTICALS INC | IONS | COM | $6,991,554 | 88,177 | SH | None |
| ELI LILLY & CO | LLY | COM | $6,587,270 | 5,492 | SH | None |
| ABIVAX SA | ABVX | SPONSORED ADS | $6,246,962 | 46,878 | SH | None |
| ALUMIS INC | ALMS | COM | $5,752,323 | 204,418 | SH | None |
| CYTOKINETICS INC | CYTK | COM NEW | $5,116,171 | 60,056 | SH | None |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $5,085,302 | 100,203 | SH | None |
| VERA THERAPEUTICS INC | VERA | CL A | $4,174,113 | 97,276 | SH | None |
| UNITEDHEALTH GROUP INC | UNH | COM | $3,995,036 | 9,612 | SH | None |
| 10X GENOMICS INC | TXG | CL A COM | $3,934,796 | 102,629 | SH | None |
| NATERA INC | NTRA | COM | $3,746,010 | 13,800 | SH | None |
| UNIQURE NV | QURE | SHS | $3,733,439 | 81,056 | SH | None |
| RHYTHM PHARMACEUTICALS INC | RYTM | COM | $3,576,165 | 32,209 | SH | None |
| MAZE THERAPEUTICS INC | MAZE | COM | $3,422,409 | 114,692 | SH | None |
| MONTE ROSA THERAPEUTICS INC | GLUE | COM | $3,318,183 | 137,115 | SH | None |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | CLASS A ORD | $3,241,619 | 166,493 | SH | None |
| ALKERMES PLC | ALKS | SHS | $3,213,700 | 61,336 | SH | None |
| LIQUIDIA CORPORATION | LQDA | COM NEW | $3,127,330 | 39,224 | SH | None |
| UNITED THERAPEUTICS CORP DEL | UTHR | COM | $2,931,300 | 5,410 | SH | None |
| GLAUKOS CORP | GKOS | COM | $2,775,913 | 19,862 | SH | None |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | COM | $2,625,763 | 32,214 | SH | None |
| AGIOS PHARMACEUTICALS INC | AGIO | COM | $2,616,255 | 70,500 | SH | None |
| CRESCENT BIOPHARMA INC. | CBIO | COM | $2,299,842 | 127,769 | SH | None |
| ASTRAZENECA PLC | AZN | ORD | $2,254,128 | 12,045 | SH | None |
| BOSTON SCIENTIFIC CORP | BSX | COM | $2,063,450 | 48,347 | SH | None |
| ADAGENE INC | ADAG | ADS | $2,050,831 | 488,293 | SH | None |
| PENUMBRA INC | PEN | COM | $1,989,225 | 6,300 | SH | None |
| INTUITIVE SURGICAL INC | ISRG | COM NEW | $1,951,813 | 4,908 | SH | None |
| VIKING THERAPEUTICS INC | VKTX | COM | $1,867,058 | 47,861 | SH | None |
| OCULAR THERAPEUTIX INC | OCUL | COM | $1,783,194 | 181,588 | SH | None |
| EQUILLIUM INC | EQ | COM | $1,769,459 | 552,956 | SH | None |
| ASCENDIS PHARMA A/S | ASND | ORD SHS | $1,753,151 | 6,573 | SH | None |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | COM NEW | $1,734,493 | 184,914 | SH | None |
| CYTOMX THERAPEUTICS INC. | CTMX | COM | $1,725,251 | 460,067 | SH | None |
| VERASTEM INC | VSTM | COM NEW | $1,638,937 | 429,041 | SH | None |
| NEKTAR THERAPEUTICS | NKTR | COM NEW | $1,564,931 | 22,417 | SH | None |
| CLEARPOINT NEURO INC | CLPT | COM | $1,492,066 | 83,636 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $1,479,139 | 13,873 | SH | None |
| CARIS LIFE SCIENCES INC | CAI | COM | $1,393,168 | 78,180 | SH | None |
| BRIDGEBIO PHARMA INC | BBIO | COM | $1,367,378 | 18,359 | SH | None |
| ZENAS BIOPHARMA INC | ZBIO | COM | $1,331,003 | 52,443 | SH | None |
| NOVABRIDGE BIOSCIENCES | NBP | SPONSORED ADS | $1,125,072 | 576,960 | SH | None |
| ESTABLISHMENT LABS HLDGS INC | ESTA | COM | $1,124,111 | 13,100 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COM | $889,305 | 47,531 | SH | None |
| GERON CORP | GERN | COM | $798,779 | 624,046 | SH | None |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | COM NEW | $709,722 | 10,110 | SH | None |
| COMPASS THERAPEUTICS INC | CMPX | COM | $604,801 | 276,165 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.